Laronidase
ApprovedTerminated 0 views this week 0 watching💤 Quiet
Interest: 35/100
35
Development Stage
✓
Pre-clinical✓
Phase 1✓
Phase 2✓
Phase 35
ApprovedIndication / Disease
Mucopolysaccharidosis I
Conditions
Mucopolysaccharidosis I, Hurler's Syndrome, Hurler-Scheie Syndrome, Scheie
Trial Timeline
Oct 22, 2010 → Dec 21, 2022
NCT ID
NCT00418821About Laronidase
Laronidase is a approved stage product being developed by Sanofi for Mucopolysaccharidosis I. The current trial status is terminated. This product is registered under clinical trial identifier NCT00418821. Target conditions include Mucopolysaccharidosis I, Hurler's Syndrome, Hurler-Scheie Syndrome.
What happened to similar drugs?
4 of 14 similar drugs in Mucopolysaccharidosis I were approved
Approved (4) Terminated (0) Active (10)
Hype Score Breakdown
Clinical
20
Activity
0
Company
15
Novelty
0
Community
0
Clinical Trials (3)
| NCT ID | Phase | Status |
|---|---|---|
| NCT05134571 | Approved | Completed |
| NCT00418821 | Approved | Terminated |
| NCT00144768 | Approved | Completed |
Competing Products
20 competing products in Mucopolysaccharidosis I